Profile
// What About Us
David W. Haas, MD
Associate CFAR Director at Vanderbilt Professor of Medicine, Pharmacology, Pathology, Microbiology & Immunology, Vanderbilt University School of Medicine; Adjunct Professor of Internal Medicine, Meharry Medical College
// About Me
Biography
Biography
Dr. Haas provides clinical expertise, a strong NIH-funded clinical trials background, and a long history at Vanderbilt. He serves as Associate CFAR Director at Vanderbilt, as well as the Director of the Clinical Sciences Core. He is directly involved in the administration of the Tennessee CFAR at Vanderbilt, as well as in the Nashville HIV/AIDS provider community. He has developed many important collaborations, particularly in areas of genomics and pharmacology. His enthusiasm and energy has already drawn many new investigators into HIV research. He has aso established connections between our campuses. He continues to foster interactions with colleagues at other academic institutions. He is directly involved in all Executive Committee and Advisory Board activities and helps monitor Scientific Working Group progress and oversees all Clinical Sciences Core activities.
More About David W. Haas, MD
During the early years of my academic career, my research focused on transcriptional regulation of protein synthesis in eukaryotic cells. More recently, and for more than 15 years, my research has largely sought to decipher the importance of human genomic differences for HIV outcomes, especially drug toxicity, efficacy, and pharmacokinetics. Since 2000 I have led the pharmacogenomics program of the NIAID-funded AIDS Clinical Trials Group (ACTG), and led the effort to create the ACTG Human DNA Repository, which represents >17,000 study participants. I have designed pharmacogenomics analyses across many trials, observational cohorts, and other databases. I have also designed and led many intensive General Clinical Research Center–based studies. Since 1994, I have directed Vanderbilt’s HIV Therapeutics Clinical Research Program. My work led to the seminal observation that a CYP2B6 variant predicts delayed clearance of efavirenz, which largely explains increased plasma exposure among individuals of African descent, and helps to predict central nervous system side effects. From 2009 to 2011, I was chair of the NIH NeuroAIDS and other End Organ Diseases (NAED) Study Section. To help translate pharmacogenomics into clinical care, I recently chaired two Clinical Pharmacogenetics Implementation Consortium guideline teams. I am highly engaged in collaborative, multidisciplinary research with an emphasis on the importance of human genomics for antiretroviral disposition, efficacy, and toxicity. I have been extensively involved designing and implementing prospective clinical trials and will enthusiastically continue to serve as the Director of the Clinical Sciences Core and Associate Director of the Tennessee CFAR.